ibalgin rapid 400 mg comprimate filmate
sanofi romania srl - ibuprofenum - comprimate filmate - 400 mg
voltaren rapid 50 mg drajeuri
novartis pharma ag - diclofenacum - drajeuri - 50 mg
xefocam rapid 8 mg comprimate filmate
acino pharma ag - lornoxicamum - comprimate filmate - 8 mg
ibalgin rapid 400 mg comprimate filmate
opella healthcare romania s.r.l. - ibuprofenum - comprimate filmate - 400 mg
xefocam rapid 8 mg comprimate filmate
acino pharma ag - lornoxicamum - comprimate filmate - 8 mg
adasuve
ferrer internacional s.a. - loxapine - schizophrenia; bipolar disorder - sistem nervos - adasuve este indicat pentru controlul rapid al agitării ușoare până la moderate la pacienții adulți cu schizofrenie sau tulburare bipolară. pacienții trebuie să primească tratament regulat imediat după controlul simptomelor acute de agitație.
tysabri
biogen netherlands b.v. - natalizumab - scleroză multiplă - imunosupresoare selective - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
test rapid betastar combo
neogen corporation, sua - set - -
fingolimod mylan
mylan ireland limited - fingolimod clorhidrat de - scleroză multiplă, scleroză multiplă recurent-remisivă - imunosupresoare - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 și 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresoare - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.